Streetwise Reports' Article Archives — January 2018 back to current month (13)

Medical Device Firm Boosts Quarterly Revenue 50% YOY (01/31/2018)

A Maxim Group report noted the recently announced revenue achieved and anticipated by this producer of cancer treatment devices.


Coverage Initiated on Developer of Potential Breast Cancer Therapy Competitor (01/31/2018)

Jason Kolbert, an analyst with Maxim Group, explained the drivers behind adding this drug and drug delivery developer to his coverage universe.


Preliminary Phase 2 Clinical Data Provides 'First Spark to Game-Changing Thesis' (01/31/2018)

H.C. Wainwright & Co. reported on the significance of preliminary data for treatments for head and neck cancer, as well as for cervical cancer.


Pancreatic Cancer Trial Data Will Be Released Soon (01/24/2018)

A biotech company that has begun clinical testing of human antibodies to treat cancers is in discussion with potential partners.


Coverage Resumed on Developer of 'Drug Candidate with Blockbuster Potential' (01/24/2018)

André Uddin, an analyst with Mackie Research Capital Corp., shared his thesis for investing in this biotech.


Regenerative Medicine Company's China Deal is 'Dramatically Transformational' (01/18/2018)

Echelon Wealth Partners detailed the terms and impact of this cell therapy developer's recent alliance in Asia.


Several Milestones on Horizon for 'Top Pick' Immunotherapy Firm (01/17/2018)

Douglas Loe, an analyst with Echelon Partners, outlined the reasons this biotech deserves Top Pick status.


Test for Personalized Approach to Hodgkin's Lymphoma Treatment Entering Final Stages Before Commercialization (01/16/2018)

One analyst believes 2018 could mark a 'dramatic turnaround' for this biotech company, which is at the forefront of using three-dimensional telomere analysis to personalize medical treatment.


Biotech Offers 'Best-in-Class Potential to Treat Alzheimer's' (01/10/2018)

André Uddin, an analyst with Mackie Research Capital Corp., discussed the implications of the latest announcement about this firm's most advanced Alzheimer's drug.


Biotech with Non-Statin Cholesterol Lowering Drug Poised for Significant Catalysts in 2018 (01/10/2018)

As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline.


2018 Biotech Watchlist: 'No One Space Is Going to Dominate' (01/10/2018)

Michael King of JMP Securities provides a comprehensive round-up of companies he has selected for the 2018 Biotech Watchlist—companies in immuno-oncology, gene editing, and other indications that he believes offer promising opportunities for patients and investors.


Firm Focused on Women's Health Posts 'Record' Sales of Treatment Device (01/10/2018)

A company marketing a product designed to enhance women's sexual function announced preliminary financial results for Q4/17 that caught the attention of several analysts.


Portfolio Manager's Biotech Watchlist Picks for 2018 (01/02/2018)

StoneCastle Investment Management has a high-growth fund that invests wherever it finds opportunities, and it is bullish on healthcare. In this interview with The Life Sciences Report, portfolio manager Bruce Campbell highlights four companies that he is putting on Streetwise Reports' 2018 Biotech Watchlist.


More Archives


2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes